ABGSC acted as sole financial advisor in connection with Oasmia’s SEK 399m rights issue

On 9 December 2019, Oasmia Pharmaceutical AB (publ) (“Oasmia”) announced the successful completion of a rights issue, issuing 199.3 million new shares at a subscription price of SEK 2, resulting in gross proceeds of SEK 399m. Oasmia intends to use the proceeds for the following activities:
• Repayment of a convertible loan
• Finance and accelerate the commercialization of Apealea, which among others include marketing, market access,
sales, manufacturing, technology transfer, machinery and equipment
• Explore new business opportunities based on the Oasmia’s proprietary XR17 platform
• Further development of the product portfolio, such as Docecal, and new partnerships
• Continued expansion into new markets, which primarily includes application for market approval in the US
• Other working capital for operations including administration